Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
A Tale of Two (or More) Targets: What We’ve Learned Building Multispecifics for Our Partners
Alloy’s perspective on the multispecific engineering problem Most protein engineers designing multispecifics today learned the craft on monoclonals, and some of the discovery and development infrastructure followed the same path. That’s a reasonable starting point. It’s also where a lot of the late-stage surprises come from. Multispecific antibodies aren’t just harder monoclonals. They’re a fundamentally […]
Advancing Differentiated Bispecific Antibodies in Autoimmune Disease
How Cantai and Alloy designed and advanced high-performance bispecifics by engineering against known failure modes from day one
Designing Bispecifics That Hold Up in the Real World
How Alloy’s integrated model helped Cantai move faster and design with greater precision
Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery
— Agreement provides Scripps Research scientists with broad access to Alloy’s fully human transgenic mouse platform, which has the power to increase the pace and success rate of antibody discovery and vaccine development efforts. — BOSTON, Mass., October 30th, 2024 – Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms […]
Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases
WALTHAM, Mass., November 20th, 2023 – Cantai Therapeutics (“Cantai”) today announced its formation and the completion of a seed financing co-led by Agent Capital and 82VS (the affiliated venture studio of Alloy Therapeutics) with additional participation from Tellus BioVentures. The proceeds will be used to develop drug candidates to treat autoimmune and inflammatory disorders by […]
Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
BOSTON, November 8th, 2023 – Alloy Therapeutics, Inc., a biotechnology ecosystem company and Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today the formation of a non-exclusive, preferred service offering to drive translation from Discovery to CMC development and clinical material supply for ecosystem partners. The organizations are collaborating to provide a […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Kent Bondensgaard and John Lippincott joined Alloy Therapeutics as key strategic leaders to support the company’s mission of democratizing access to foundational drug discovery technologies. Their combined expertise in corporate development and clinical strategy enhances Alloy’s ability to scale its platform services and foster long-term partnerships with biotechnology and pharmaceutical innovators. Alloy Antibody Discovery Services […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
Alloy Therapeutics secured $42 million in Series D financing to continue the expansion of its democratized ecosystem, which provides drug developers with open access to foundational antibody discovery platforms and services. This funding supports the company’s commitment to scaling its technology infrastructure, enabling scientific partners to advance biotherapeutic pipelines from discovery to the clinic. — […]